Overview
Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Completed
Trial end date:
2006-06-28
2006-06-28
Target enrollment:
0
0
Participant gender:
All
All
Summary
To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability of GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2 diabetes mellitus (T2DM) patients.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
GlaxoSmithKline
Criteria
Inclusion criteria:- T2DM diagnosed at least 3 months prior to Screening and fasting plasma glucose (FPG)
level <280mg/dL at the Screening visit.
- Concurrent T2DM therapy: Must be diet controlled - OR - not taking more than 2 oral
anti-diabetic agents, and willing to withdraw from these treatments 2 weeks prior to
the first dosing.
Exclusion criteria:
- Must not have any other major illness other than diabetes